AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29715056 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax for patients who received prior kinase inhibitors
Number of subjects: 158
Study 29715056 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 158
Study 29715516 — intervention group
Group type: EXPERIMENTAL
Intervention: VVS prediction algorithm with noninvasive HR and SBP analysis
Number of subjects: 140
Study 29715516 — intervention group
Group type: EXPERIMENTAL
Intervention: VVS prediction algorithm using only HR and HR variability (without SBP)
Number of subjects: 140
Study 29715516 — intervention group
Group type: EXPERIMENTAL
Intervention: VVS prediction algorithm
Number of subjects: 140
Study 29716439 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29716559 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-week diabetes prevention program including 5 half-day group sessions and web/telephone-based support
Number of subjects: 59
Study 29716559 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 59
Study 29716580 — intervention group
Group type: EXPERIMENTAL
Intervention: TCApp combined with standard face-to-face CBT
Number of subjects: 250
Study 29716580 — intervention group
Group type: COMPARATOR
Intervention: Standard face-to-face CBT alone
Number of subjects: 250
Study 29716605 — intervention group
Group type: EXPERIMENTAL
Intervention: GSA-Online plus
Number of subjects: 0
Study 29716640 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg loading dose followed by 5 mg/kg/h maintenance infusion)
Number of subjects: 147
Study 29716640 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 147
Study 29717148 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV sequence data analysis
Number of subjects: 2774
Study 29717148 — intervention group
Group type: EXPERIMENTAL
Intervention: Clustering individuals
Number of subjects: 2774
Study 29717148 — intervention group
Group type: EXPERIMENTAL
Intervention: Clusters consisting exclusively of men
Number of subjects: 2774
Study 29717148 — intervention group
Group type: EXPERIMENTAL
Intervention: Clusters containing sequences from more than one region
Number of subjects: 2774
Study 29717148 — intervention group
Group type: EXPERIMENTAL
Intervention: Clusters linking sequences with Los Alamos database
Number of subjects: 2774
Study 29717351 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon Capsule Endoscopy (CCE)
Number of subjects: 255
Study 29717351 — intervention group
Group type: EXPERIMENTAL
Intervention: Model predicting HP polyp size
Number of subjects: 255
Study 29717760 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic and vascular diseases
Number of subjects: 1181
Study 29717760 — intervention group
Group type: EXPERIMENTAL
Intervention: Musculo-skeletal diseases
Number of subjects: 1181
Study 29717760 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory diseases
Number of subjects: 1181
Study 29718281 — intervention group
Group type: EXPERIMENTAL
Intervention: Alström syndrome (AS) patients
Number of subjects: 38
Study 29718281 — intervention group
Group type: COMPARATOR
Intervention: BMI-matched controls
Number of subjects: 38
Study 29718334 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment
Number of subjects: 20
Study 29718390 — intervention group
Group type: COMPARATOR
Intervention: 10 mg/kg rifampicin (reference arm)
Number of subjects: 83
Study 29718390 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg rifampicin
Number of subjects: 83
Study 29718390 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/kg rifampicin
Number of subjects: 83
Study 29718390 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg rifampicin
Number of subjects: 83
Study 29718390 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg/kg rifampicin
Number of subjects: 83
Study 29718390 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/kg rifampicin
Number of subjects: 83
Study 29718390 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/kg rifampicin (predicted)
Number of subjects: 83
Study 29719139 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus surgery
Number of subjects: 128
Study 29719414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 0
Study 29719492 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 2700
Study 29719517 — intervention group
Group type: EXPERIMENTAL
Intervention: Play2Sleep intervention during a home visit
Number of subjects: 60
Study 29719517 — intervention group
Group type: COMPARATOR
Intervention: Standard public health nursing information
Number of subjects: 60
Study 29719876 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus individualised caregiver education
Number of subjects: 324
Study 29719876 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 324
Study 29720163 — intervention group
Group type: EXPERIMENTAL
Intervention: mRDT tested children in moderate-to-high transmission setting
Number of subjects: 18497
Study 29720163 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-referral rectal artesunate treatment
Number of subjects: 18497
Study 29720163 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT prescribed in low-transmission setting
Number of subjects: 18497
Study 29720163 — intervention group
Group type: COMPARATOR
Intervention: CHW referral advice
Number of subjects: 18497
Study 29720190 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional dyspepsia patients
Number of subjects: 124
Study 29720196 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical fitness (measured with 11 fitness tests covering flexibility, strength, balance, and endurance)
Number of subjects: 62
Study 29720196 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional reach (part of physical fitness assessment)
Number of subjects: 62
Study 29720224 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and cyclophosphamide (TC)
Number of subjects: 30
Study 29720224 — intervention group
Group type: COMPARATOR
Intervention: Non-TC chemotherapy regimens
Number of subjects: 30
Study 29720224 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 29720225 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised endurance exercise training combined with tocilizumab (ET)
Number of subjects: 75
Study 29720225 — intervention group
Group type: EXPERIMENTAL
Intervention: No exercise combined with tocilizumab (NT)
Number of subjects: 75
Study 29720225 — intervention group
Group type: COMPARATOR
Intervention: Supervised endurance exercise training combined with saline (EP)
Number of subjects: 75
Study 29720225 — intervention group
Group type: COMPARATOR
Intervention: No exercise combined with placebo (NP)
Number of subjects: 75
Study 29720225 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise and placebo (RP)
Number of subjects: 75
Study 29720248 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion strategy
Number of subjects: 0
Study 29720248 — intervention group
Group type: EXPERIMENTAL
Intervention: Definition of further bleeding (varied criteria, assessment, and time-point)
Number of subjects: 0
Study 29720277 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal PEEP titration
Number of subjects: 0
Study 29720277 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume adjustment
Number of subjects: 0
Study 29720397 — intervention group
Group type: EXPERIMENTAL
Intervention: SERMs
Number of subjects: 22969
Study 29720397 — intervention group
Group type: COMPARATOR
Intervention: AIs
Number of subjects: 22969
Study 29720439 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-based vascular neurologist (TM-VN)
Number of subjects: 50
Study 29720439 — intervention group
Group type: COMPARATOR
Intervention: Onboard vascular neurologist (OB-VN)
Number of subjects: 50
Study 29720487 — intervention group
Group type: EXPERIMENTAL
Intervention: High heterogeneity of intratumoral metabolic activity as assessed by baseline 18FDG-PET/CT scan
Number of subjects: 0
Study 29720487 — intervention group
Group type: COMPARATOR
Intervention: First-line therapy for PMBCL
Number of subjects: 0
Study 29720734 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF, cladribine, high-dose cytarabine, and dose-escalated mitoxantrone (GCLAM)
Number of subjects: 121
Study 29720734 — intervention group
Group type: COMPARATOR
Intervention: 7 + 3 regimen (not explicitly detailed in the abstract)
Number of subjects: 121
Study 29721017 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated levels of miR-24, miR-30d, and miR-146a in subjects with obesity
Number of subjects: 0
Study 29721017 — intervention group
Group type: EXPERIMENTAL
Intervention: SFRP4 levels in AbdAT
Number of subjects: 0
Study 29721364 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio Recording for Independent Confirmation of Clinical Assessments
Number of subjects: 0
Study 29721378 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib (BRAF inhibitor) and aldesleukin (interleukin-2)
Number of subjects: 0
Study 29721378 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29721545 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery (TORS) with cervical-transoral robotic oropharyngectomy and free flap reconstruction
Number of subjects: 3
Study 29722789 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 0
Study 29722789 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study 29722789 — intervention group
Group type: COMPARATOR
Intervention: Weighted prevalence of regorafenib toxicity profile and dose reduction
Number of subjects: 0
Study 29722823 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 followed by PPV23
Number of subjects: 40
Study 29722823 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 40
Study 29722823 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV23
Number of subjects: 40
Study 29722835 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter salvage strategy (successful antimicrobial therapy with retained CVC at discharge)
Number of subjects: 715
Study 29722835 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoinfections
Number of subjects: 715
Study 29722835 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyinfections
Number of subjects: 715
Study 29722835 — intervention group
Group type: EXPERIMENTAL
Intervention: Causative microorganism: Coagulase-negative Staphylococci (CoNS)
Number of subjects: 715
Study 29722835 — intervention group
Group type: EXPERIMENTAL
Intervention: Causative microorganism: Staphylococcus aureus
Number of subjects: 715
Study 29722835 — intervention group
Group type: EXPERIMENTAL
Intervention: Causative microorganism: Enterobacteriaceae
Number of subjects: 715
Study 29722835 — intervention group
Group type: COMPARATOR
Intervention: Retained CVC
Number of subjects: 715
Study 29722835 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterobacteriaceae
Number of subjects: 715
Study 29722835 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall CRBSI
Number of subjects: 715
Study 29722835 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rate
Number of subjects: 715
Study 29722835 — intervention group
Group type: EXPERIMENTAL
Intervention: CRBSI relapse
Number of subjects: 715
Study 29722835 — intervention group
Group type: EXPERIMENTAL
Intervention: CRBSI recurrence
Number of subjects: 715
Study 29722836 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine intake ≥250-299 μg/d in 7- to 10-y-old children
Number of subjects: 2224
Study 29722836 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine intake ≥300-399 μg/d in 11- to 14-y-old children
Number of subjects: 2224
Study 29722836 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual iodine intake
Number of subjects: 2224
Study 29722836 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid volume and goiter
Number of subjects: 2224
Study 29722836 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended iodine intake levels
Number of subjects: 2224
Study 29722838 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal intake of total vitamin A (≥2031 RAEs/d)
Number of subjects: 61676
Study 29722838 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal intake of total vitamin D (≥13.6 µg/d)
Number of subjects: 61676
Study 29722838 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal intake of both vitamins A and D in the highest quintiles
Number of subjects: 61676
Study 29722838 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant supplementation with vitamin D or cod liver oil
Number of subjects: 61676
Study 29722838 — intervention group
Group type: EXPERIMENTAL
Intervention: Excess vitamin A (≥2.5 times the recommended intake) during pregnancy
Number of subjects: 61676
Study 29722838 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D intake close to recommendations
Number of subjects: 61676
Study 29722851 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-to-magnesium ratio (Ca:Mg) intake, tertile 2
Number of subjects: 2060
Study 29722851 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-to-magnesium ratio (Ca:Mg) intake, tertile 3
Number of subjects: 2060
Study 29722851 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-to-magnesium ratio (Ca:Mg) intake, tertile 3 (stratified by race)
Number of subjects: 2060
Study 29722851 — intervention group
Group type: COMPARATOR
Intervention: Whole-fat milk consumption
Number of subjects: 2060
Study 29723161 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin treatment for 14 days (initiation cohort)
Number of subjects: 22
Study 29723161 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin treatment for 6 months on an ad libitum diet (initiation cohort)
Number of subjects: 22
Study 29723161 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal from metreleptin for 14 days (withdrawal cohort)
Number of subjects: 22
Study 29723397 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 50 mg daily
Number of subjects: 75
Study 29723634 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee replacement (TKR) followed by non-surgical treatment
Number of subjects: 200
Study 29723634 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical treatment alone
Number of subjects: 200
Study 29723634 — intervention group
Group type: COMPARATOR
Intervention: Written advice
Number of subjects: 200
Study 29723689 — intervention group
Group type: EXPERIMENTAL
Intervention: MH test (in vitro method using monocyte-derived hepatocyte-like cells)
Number of subjects: 40
Study 29723689 — intervention group
Group type: COMPARATOR
Intervention: Drugs not toxic to MH cells
Number of subjects: 40
Study 29724167 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib (960 mg twice daily)
Number of subjects: 0
Study 29724294 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCC2 rs2273697 AA genotype
Number of subjects: 187
Study 29724397 — intervention group
Group type: EXPERIMENTAL
Intervention: GFF MDI 14.4/10 μg (equivalent to glycopyrrolate/formoterol fumarate 18/9.6 μg) twice daily for 7 days with VHC
Number of subjects: 80
Study 29724397 — intervention group
Group type: COMPARATOR
Intervention: GFF MDI 14.4/10 μg (equivalent to glycopyrrolate/formoterol fumarate 18/9.6 μg) twice daily for 7 days without VHC
Number of subjects: 80
Study 29724706 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-free + challenge walking
Number of subjects: 30
Study 29724706 — intervention group
Group type: COMPARATOR
Intervention: Hands-free walking (control group)
Number of subjects: 30
Study 29724706 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 29724735 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic stress model during pregnancy
Number of subjects: 260
Study 29724735 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary approach including psychological resources and biophysiological and genetic profiles
Number of subjects: 260
Study 29724899 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinometostat (EPZ-5676)
Number of subjects: 0
Study 29724902 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m²
Number of subjects: 0
Study 29724902 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor
Number of subjects: 0
Study 29724973 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational registry of heart failure with mid-range and preserved ejection fraction (APOLLON trial)
Number of subjects: 1065
Study 29725840 — intervention group
Group type: EXPERIMENTAL
Intervention: Pallidal deep brain stimulation (Gp-DBS)
Number of subjects: 2
Study 29726024 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention including educational steps (written information in child's native language and follow-up telephone calls) and monitoring steps (Eidus-Hamilton test and follow-up questionnaire)
Number of subjects: 359
Study 29726782 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser interstitial thermal (LITT) ablation
Number of subjects: 42
Study 29726923 — intervention group
Group type: EXPERIMENTAL
Intervention: Brontictuzumab administered intravenously at 1.5 mg/kg every 3 weeks (Q3W) during expansion phase.
Number of subjects: 48
Study 29726923 — intervention group
Group type: EXPERIMENTAL
Intervention: Brontictuzumab administered intravenously at various dose levels during dose escalation.
Number of subjects: 48
Study 29726948 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained recovery from MAM
Number of subjects: 1487
Study 29726948 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapsed to MAM once
Number of subjects: 1487
Study 29726948 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapsed to MAM multiple times
Number of subjects: 1487
Study 29726948 — intervention group
Group type: EXPERIMENTAL
Intervention: Developed severe acute malnutrition (SAM)
Number of subjects: 1487
Study 29726948 — intervention group
Group type: EXPERIMENTAL
Intervention: Declining HAZ
Number of subjects: 1487
Study 29727073 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusions (0.5 mg/kg)
Number of subjects: 15
Study 29727383 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) + Ribavirin (RBV) for 24 weeks
Number of subjects: 62
Study 29727383 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) + Simeprevir for 12 weeks
Number of subjects: 62
Study 29727383 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) + Daclatasvir for 24 weeks
Number of subjects: 62
Study 29727383 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) + Daclatasvir + Ribavirin (RBV) for 12 weeks
Number of subjects: 62
Study 29727383 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 62
Study 29727383 — intervention group
Group type: COMPARATOR
Intervention: HCC recurrence
Number of subjects: 62
Study 29728114 — intervention group
Group type: EXPERIMENTAL
Intervention: BALANCE Dietary Index (DI)
Number of subjects: 2044
Study 29728137 — intervention group
Group type: EXPERIMENTAL
Intervention: High MIF levels
Number of subjects: 62
Study 29728137 — intervention group
Group type: EXPERIMENTAL
Intervention: MIF levels
Number of subjects: 62
Study 29728150 — intervention group
Group type: EXPERIMENTAL
Intervention: PRE-DELIRIC
Number of subjects: 2178
Study 29728150 — intervention group
Group type: COMPARATOR
Intervention: E-PRE-DELIRIC
Number of subjects: 2178
Study 29728150 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage calculation using E-PRE-DELIRIC and updated with PRE-DELIRIC after 24 hours
Number of subjects: 2178
Study 29728199 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care device (i-STAT, Abbott Laboratories)
Number of subjects: 1170
Study 29728717 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylalanine
Number of subjects: 3587
Study 29728717 — intervention group
Group type: EXPERIMENTAL
Intervention: Histidine
Number of subjects: 3587
Study 29728717 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine
Number of subjects: 3587
Study 29728717 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanine
Number of subjects: 3587
Study 29728717 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine
Number of subjects: 3587
Study 29728717 — intervention group
Group type: EXPERIMENTAL
Intervention: Valine
Number of subjects: 3587
Study 29728717 — intervention group
Group type: EXPERIMENTAL
Intervention: All amino acids
Number of subjects: 3587
Study 29728755 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (2.68-3.11 µg/kg) co-administered with propofol (3 mg/kg)
Number of subjects: 27
Study 29728798 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan-based chemotherapy
Number of subjects: 164
Study 29729048 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective period
Number of subjects: 27585
Study 29729048 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes in Northern Europe/Canada
Number of subjects: 27585
Study 29729048 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes in Eastern Europe
Number of subjects: 27585
Study 29729048 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes in South East Asia
Number of subjects: 27585
Study 29729048 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes in South East Asia
Number of subjects: 27585
Study 29729048 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes in Eastern Europe
Number of subjects: 27585
Study 29729048 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes in Russia
Number of subjects: 27585
Study 29729048 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes in Russia
Number of subjects: 27585
Study 29729048 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes in Latin America
Number of subjects: 27585
Study 29729048 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes in Latin America
Number of subjects: 27585
Study 29729048 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes in Northern Europe/Canada
Number of subjects: 27585
Study 29729048 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose cut-off for Type 1 diabetes
Number of subjects: 27585
Study 29729048 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose cut-off for Type 2 diabetes
Number of subjects: 27585
Study 29729809 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat and Extend Ranibizumab
Number of subjects: 0
Study 29730244 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers related to marginalization
Number of subjects: 395